PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33167484-4 2020 This study aimed to investigate the long-lasting analgesic effect of eugenol alone, as well as that of the combination of eugenol as a noxious-heat-sensitive transient receptor potential vanilloid 1 (TRPV1) channel agonist and a permanently charged sodium channel blocker (QX-314), on neuronal excitability in trigeminal ganglion (TG) neurons. Eugenol 122-129 transient receptor potential cation channel subfamily V member 1 Homo sapiens 158-198 33167484-4 2020 This study aimed to investigate the long-lasting analgesic effect of eugenol alone, as well as that of the combination of eugenol as a noxious-heat-sensitive transient receptor potential vanilloid 1 (TRPV1) channel agonist and a permanently charged sodium channel blocker (QX-314), on neuronal excitability in trigeminal ganglion (TG) neurons. Eugenol 122-129 transient receptor potential cation channel subfamily V member 1 Homo sapiens 200-205 33167484-11 2020 Taken together, our results suggest that, in contrast to the effect of eugenol alone, the combination of eugenol and QX-314 irreversibly and selectively blocked VGSCs in TG neurons expressing TRPV1. Eugenol 105-112 transient receptor potential cation channel subfamily V member 1 Homo sapiens 192-197 17720863-2 2007 Eugenol inhibits voltage-activated Na(+) and Ca(2+) channels in a transient receptor potential vanilloid 1 (TRPV1)-independent manner. Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 66-106 17720863-2 2007 Eugenol inhibits voltage-activated Na(+) and Ca(2+) channels in a transient receptor potential vanilloid 1 (TRPV1)-independent manner. Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 108-113 17720863-6 2007 Eugenol inhibited human Kv1.5 currents stably expressed in Ltk(-) cells, where TRPV1 is not endogenously expressed. Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 79-84 17720863-7 2007 We conclude that eugenol inhibits voltage-gated K(+) currents in a TRPV1-independent manner. Eugenol 17-24 transient receptor potential cation channel subfamily V member 1 Homo sapiens 67-72 33839411-7 2021 Under low pH conditions, low concentrations of eugenol only enhanced the proton-induced TRPV1 currents, whereas high eugenol concentrations initially potentiated but then immediately abrogated TRPV1 currents. Eugenol 47-54 transient receptor potential cation channel subfamily V member 1 Homo sapiens 88-93 33839411-7 2021 Under low pH conditions, low concentrations of eugenol only enhanced the proton-induced TRPV1 currents, whereas high eugenol concentrations initially potentiated but then immediately abrogated TRPV1 currents. Eugenol 117-124 transient receptor potential cation channel subfamily V member 1 Homo sapiens 193-198 33839411-9 2021 Our results demonstrate that eugenol is a mode-selective antagonist of TRPV1 and can be evaluated as a lead compound of analgesics targeting TRPV1 without serious side effects. Eugenol 29-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 71-76 33839411-9 2021 Our results demonstrate that eugenol is a mode-selective antagonist of TRPV1 and can be evaluated as a lead compound of analgesics targeting TRPV1 without serious side effects. Eugenol 29-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 141-146 33456468-0 2020 Polymodal Activation and Desensitization of TRPV1 Receptor in Human Odontoblasts-Like Cells with Eugenol. Eugenol 97-104 transient receptor potential cation channel subfamily V member 1 Homo sapiens 44-49 24384226-2 2014 The structural similarity of eugenol to cinnamaldehyde, an active ligand for transient receptor potential ankyrin 1 (TRPA1), suggests that eugenol might produce its effect via TRPA1, in addition to TRPV1 as we reported previously. Eugenol 29-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 198-203 24384226-2 2014 The structural similarity of eugenol to cinnamaldehyde, an active ligand for transient receptor potential ankyrin 1 (TRPA1), suggests that eugenol might produce its effect via TRPA1, in addition to TRPV1 as we reported previously. Eugenol 139-146 transient receptor potential cation channel subfamily V member 1 Homo sapiens 198-203 23791894-11 2013 The brief heat hyperalgesia following eugenol may involve a TRPV3-mediated enhancement of thermal gating of TRPV1 expressed in lingual polymodal nociceptors. Eugenol 38-45 transient receptor potential cation channel subfamily V member 1 Homo sapiens 108-113 19967073-6 2008 Eugenol inhibited not only Ca(2+) transients evoked by alpha ,beta-meATP, the selective P2X(3) agonist, in capsaicin-insensitive TG neurons, but also ATP-induced currents in P2X(3)-expressing HEK293 cells without co-expression of transient receptor potential vanilloid 1 (TRPV1). Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 230-270 19967073-6 2008 Eugenol inhibited not only Ca(2+) transients evoked by alpha ,beta-meATP, the selective P2X(3) agonist, in capsaicin-insensitive TG neurons, but also ATP-induced currents in P2X(3)-expressing HEK293 cells without co-expression of transient receptor potential vanilloid 1 (TRPV1). Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 272-277 19967073-7 2008 We suggest, therefore, that eugenol inhibits P2X(3) currents in a TRPV1-independent manner, which contributes to its analgesic effect. Eugenol 28-35 transient receptor potential cation channel subfamily V member 1 Homo sapiens 66-71 18218839-4 2008 Eugenol inhibited calcium currents in the E52 cell line, stably expressing the human Ca(V)2.3 calcium channels, where TRPV1 is not endogenously expressed. Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 118-123 16109996-4 2005 The HVACC inhibition by eugenol was not blocked by capsazepine, a competitive transient receptor potential vanilloid 1 (TRPV1) antagonist. Eugenol 24-31 transient receptor potential cation channel subfamily V member 1 Homo sapiens 78-118 16109996-4 2005 The HVACC inhibition by eugenol was not blocked by capsazepine, a competitive transient receptor potential vanilloid 1 (TRPV1) antagonist. Eugenol 24-31 transient receptor potential cation channel subfamily V member 1 Homo sapiens 120-125 16109996-5 2005 Eugenol inhibited N-type calcium currents in the cell line C2D7, stably expressing the human N-type calcium channels, where TRPV1 was not endogenously expressed. Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 124-129 14514756-0 2003 Activation of vanilloid receptor 1 (VR1) by eugenol. Eugenol 44-51 transient receptor potential cation channel subfamily V member 1 Homo sapiens 14-34 14514756-0 2003 Activation of vanilloid receptor 1 (VR1) by eugenol. Eugenol 44-51 transient receptor potential cation channel subfamily V member 1 Homo sapiens 36-39 14514756-3 2003 In vanilloid receptor 1 (VR1)-expressing human embryonic kidney (HEK) 293 cells and trigeminal ganglion (TG) neurons, eugenol activated inward currents, whereas capsazepine, a competitive VR antagonist, and ruthenium red (RR), a functional VR antagonist, completely blocked eugenol-induced inward currents. Eugenol 118-125 transient receptor potential cation channel subfamily V member 1 Homo sapiens 3-23 14514756-3 2003 In vanilloid receptor 1 (VR1)-expressing human embryonic kidney (HEK) 293 cells and trigeminal ganglion (TG) neurons, eugenol activated inward currents, whereas capsazepine, a competitive VR antagonist, and ruthenium red (RR), a functional VR antagonist, completely blocked eugenol-induced inward currents. Eugenol 118-125 transient receptor potential cation channel subfamily V member 1 Homo sapiens 25-28 14514756-4 2003 Moreover, eugenol caused elevation of [Ca(2+)](i), and this was completely abolished by both capsazepine and ruthenium red in VR1-expressing HEK 293 cells and TG neurons. Eugenol 10-17 transient receptor potential cation channel subfamily V member 1 Homo sapiens 126-129 14514756-5 2003 Our results provide strong evidence that eugenol produces its effects, at least in part, via VR1 expressed by the sensory nerve endings in the teeth. Eugenol 41-48 transient receptor potential cation channel subfamily V member 1 Homo sapiens 93-96